tiprankstipranks
Trending News
More News >
Immunome (IMNM)
NASDAQ:IMNM
US Market

Immunome (IMNM) Income Statement

Compare
271 Followers

Immunome Income Statement

Last quarter (Q4 2024), Immunome's total revenue was $2.74M, a decrease of -28.44% from the same quarter last year. In Q4, Immunome's net income was $-80.25M. See Immunome’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 9.04M$ 14.02M$ 0.00$ 0.00$ 0.00
Gross Profit
$ 9.04M$ -8.91M$ -631.00K$ -755.00K$ -755.00K
Operating Expenses
$ 314.84M$ 122.82M$ 36.90M$ 25.20M$ 12.26M
Depreciation and Amortization
$ 2.10M$ 728.00K$ 631.00K$ 755.00K$ 755.00K
EBITDA
$ -151.35M$ -28.27M$ -36.27M$ -23.95M$ -17.04M
Operating Income
$ -305.80M$ -109.53M$ -36.90M$ -25.20M$ -12.26M
Other Income/Expenses
$ 12.84M$ 2.72M$ 5.00K$ 493.00K$ -5.58M
Pretax Income
$ -292.96M$ -106.81M$ -36.90M$ -24.71M$ -17.84M
Net Income
$ -292.96M$ -106.81M$ -37.51M$ -24.47M$ -17.12M
Per Share Metrics
Basic EPS
$ -5.00$ -5.38$ -3.09$ -2.12$ -1.69
Diluted EPS
$ -5.00$ -5.38$ -3.09$ -2.12$ -1.69
Weighted Average Shares Outstanding
58.64M 19.84M 12.13M 11.54M 10.11M
Weighted Average Shares Outstanding (Diluted)
58.64M 19.84M 12.13M 11.54M 10.11M
Currency in USD

Immunome Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis